Advancing a novel approach to obesity for better outcomes
We are harnessing the power of activin biology to develop therapeutics for obesity and cardiometabolic disease.
Our clinically-validated lead candidate, bimagrumab, is a potent, first-in-class monoclonal antibody that blocks activin type II receptors, directly targeting fat and muscle tissue, and shows promise for significant and lasting impact in patients with obesity and cardiometabolic diseases.
Bimagrumab is poised to usher in a new treatment paradigm—first for obesity, and then more broadly across cardiometabolic diseases.
Mechanism of Action
Bimagrumab targets activin signaling to help people achieve and maintain substantial fat loss without losing muscle mass.
Obesity Landscape
Obesity is one of the leading chronic disease epidemics of our age, affecting more than 40% of American adults today.
Pipeline
We are currently evaluating bimagrumab in a Phase 2b study for obesity, with additional cardiometabolic indications to follow.
